CDIX Revenue Soars 70% But Mounting Debt Widens Net Loss

TL;DR

**CDIX is a high-growth, high-debt play; revenue is up, but interest expense is crushing profitability, making it a risky bet.**

AI Summary

Cardiff Lexington Corp (CDIX) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $8,763,314, up from $5,149,416 in the prior year, a 70.2% increase. Gross profit also surged to $5,445,371 from $2,407,651, an impressive 126.1% increase. Despite this revenue growth, the company's net loss for the period widened to $2,821,471, compared to a net loss of $2,392,657 in the same period last year, primarily due to a substantial rise in interest expense, which hit $4,594,714, up from $1,803,657. Total current liabilities increased to $22,380,748 as of September 30, 2025, from $15,886,803 at December 31, 2024, driven largely by a significant increase in the line of credit to $14,727,190 from $8,645,991. Cash decreased sharply to $232,033 from $1,188,185 at year-end 2024. The company continues to operate through its Nova Ortho and Spine, LLC subsidiary, focusing on healthcare acquisitions. A 1-for-75,000 reverse stock split was effected on January 9, 2024, impacting share and per-share data. The company's accumulated deficit grew to $(76,533,799) by September 30, 2025.

Why It Matters

Cardiff Lexington's substantial revenue growth, primarily through its Nova Ortho and Spine subsidiary, indicates strong operational performance in its healthcare acquisition strategy. However, the dramatic increase in interest expense and overall liabilities, particularly the line of credit, raises significant concerns about financial sustainability and leverage for investors. This could impact the company's ability to fund future acquisitions or operations, potentially limiting its competitive position against better-capitalized rivals. Employees and customers of Nova Ortho and Spine might see continued operational stability, but the broader market will scrutinize CDIX's ability to convert revenue growth into profitability amidst rising debt costs.

Risk Assessment

Risk Level: high — The company's net loss widened to $2,821,471 for the nine months ended September 30, 2025, from $2,392,657 in the prior year, primarily due to a massive increase in interest expense to $4,594,714. Current liabilities significantly outstrip current assets ($22,380,748 vs. $21,044,546), and cash reserves plummeted from $1,188,185 to $232,033, indicating severe liquidity challenges.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the rapidly deteriorating cash position and ballooning interest expenses that are eroding revenue gains. The significant increase in the line of credit suggests reliance on debt to sustain operations, which is unsustainable long-term without a clear path to profitability.

Financial Highlights

revenue

$8.76M

total Assets

$27.61M

total Debt

$22.60M

net Income

$(2.82M)

eps

$(0.20)

gross Margin

62.1%

cash Position

$232K

revenue Growth

+70.2%

Key Numbers

• $8.76M — Revenue (Increased 70.2% for the nine months ended September 30, 2025, from $5.15M in 2024.)
• $(2.82M) — Net Loss (Widened from $(2.39M) in the prior year, primarily due to increased interest expense.)
• $4.59M — Interest Expense (Increased significantly from $1.80M in the prior year, impacting profitability.)
• $232K — Cash (Decreased sharply from $1.19M at December 31, 2024, indicating liquidity strain.)
• $14.73M — Line of Credit (Increased from $8.65M at December 31, 2024, contributing to higher liabilities.)
• $(0.20) — Basic and Diluted Loss Per Share (Continuing Operations) (Improved from $(0.30) in the prior year, despite the overall net loss widening.)
• $22.38M — Total Current Liabilities (Increased from $15.89M at December 31, 2024, indicating higher short-term obligations.)
• $(76.53M) — Accumulated Deficit (Increased from $(72.95M) at December 31, 2024, reflecting ongoing losses.)
• 1-for-75,000 — Reverse Stock Split (Effected on January 9, 2024, impacting share count and per-share metrics.)
• 70.2% — Revenue Growth Percentage (Percentage increase in revenue for the nine months ended September 30, 2025, compared to 2024.)

Key Players & Entities

• Cardiff Lexington Corporation (company) — registrant
• Nova Ortho and Spine, LLC (company) — primary operating subsidiary
• Edge View Properties, Inc. (company) — subsidiary
• Red Rock Travel Group, LLC (company) — discontinued entity
• Platinum Tax Defenders (company) — previously owned and sold business
• SEC (regulator) — Securities and Exchange Commission
• $8,763,314 (dollar_amount) — total revenue for nine months ended September 30, 2025
• $4,594,714 (dollar_amount) — interest expense for nine months ended September 30, 2025
• $2,821,471 (dollar_amount) — net loss for nine months ended September 30, 2025
• $232,033 (dollar_amount) — cash balance as of September 30, 2025

FAQ

Risk Factors

• Increased Debt and Interest Expense [high — financial]: The company's line of credit increased significantly to $14.73 million from $8.65 million, contributing to a rise in total current liabilities to $22.38 million. This increased leverage is accompanied by a substantial surge in interest expense to $4.59 million for the nine months ended September 30, 2025, up from $1.80 million in the prior year, directly impacting net loss.
• Deteriorating Liquidity Position [high — financial]: Cash reserves have sharply declined to $232,033 as of September 30, 2025, from $1.19 million at the end of 2024. This significant reduction in cash, coupled with increasing liabilities, indicates a potential strain on the company's ability to meet its short-term obligations.
• Growing Accumulated Deficit [medium — financial]: The company's accumulated deficit has expanded to $(76.53) million as of September 30, 2025, from $(72.95) million at December 31, 2024. This ongoing increase reflects persistent net losses, highlighting the company's long-term unprofitability.
• Dependence on Subsidiary Performance [medium — operational]: Cardiff Lexington Corp continues to operate through its Nova Ortho and Spine, LLC subsidiary. The financial performance and strategic execution of this single operating segment are critical to the company's overall success and revenue generation.
• Impact of Reverse Stock Split [low — financial]: A 1-for-75,000 reverse stock split was effected on January 9, 2024. While this can adjust share price and count, it does not fundamentally alter the company's financial health or operational performance, but it significantly impacts per-share metrics and investor perception.

Industry Context

Cardiff Lexington Corp operates within the healthcare sector, specifically focusing on acquisitions through its Nova Ortho and Spine, LLC subsidiary. This segment is characterized by consolidation trends and the need for significant capital to fund acquisitions. The industry faces ongoing regulatory scrutiny and evolving reimbursement landscapes, requiring companies to maintain strong financial discipline and operational efficiency.

Regulatory Implications

As a publicly traded company, Cardiff Lexington is subject to SEC regulations and reporting requirements. The company's financial condition, particularly its increasing debt and widening losses, could attract regulatory attention regarding its going concern status. Compliance with healthcare regulations related to its subsidiary's operations is also paramount.

What Investors Should Do

1. Monitor cash burn rate and debt levels closely.
2. Evaluate the sustainability of revenue growth against rising costs.
3. Analyze the terms and covenants of the increased line of credit.
4. Assess the strategic rationale and execution of acquisition strategy.

Key Dates

• 2024-01-09: Reverse Stock Split — A 1-for-75,000 reverse stock split was enacted, significantly reducing the number of outstanding shares and impacting per-share data for all periods presented.
• 2025-09-30: Quarterly Reporting Period End — The 10-Q filing covers the nine months ended this date, showing substantial revenue growth but a widening net loss due to increased interest expenses and a deteriorating cash position.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative balance in retained earnings. (Indicates the company has historically incurred more losses than profits, with the deficit growing to $(76.53) million.)

Line of Credit

A flexible loan that allows a borrower to draw funds up to a certain limit, repay them, and then borrow them again. It is typically used for short-term working capital needs. (The company's line of credit increased to $14.73 million, contributing significantly to its current liabilities and indicating increased reliance on short-term debt.)

Mezzanine Equity

A hybrid form of financing that blends debt and equity features. It is subordinate to senior debt but senior to common equity. (Cardiff Lexington has substantial mezzanine equity, primarily from redeemable convertible preferred stock, totaling $5.38 million, which carries specific redemption rights and obligations.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (A 1-for-75,000 reverse split was executed, drastically altering share counts and per-share metrics, making historical comparisons on a per-share basis challenging without adjustment.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Cardiff Lexington Corp has demonstrated impressive revenue growth of 70.2%, reaching $8.76 million. However, this top-line expansion has been overshadowed by a significant increase in interest expenses, which more than doubled, leading to a wider net loss of $2.82 million. The company's liquidity has also deteriorated, with cash falling sharply to $232,033 from $1.19 million, while total current liabilities have surged by over $6.5 million, primarily driven by a larger line of credit. The accumulated deficit continues to grow, underscoring ongoing profitability challenges despite revenue gains.

Key Financial Figures

• $0.001 — ed Stock - 3,000,000 shares authorized, $0.001 par value, stated value $ 4.00 , 1,006,
• $83,669 — assets and right of use liabilities by $83,669 and $139,232, respectively. For the nin
• $139,232 — right of use liabilities by $83,669 and $139,232, respectively. For the nine months ende
• $224,179 — right of use liabilities by a total of $224,179. The accompanying notes are an integra

Filing Documents

• cardiff_i10q-093025.htm (10-Q) — 1437KB
• cardiff_ex0324.htm (EX-3.24) — 1KB
• cardiff_ex0401.htm (EX-4.1) — 57KB
• cardiff_ex0403.htm (EX-4.3) — 74KB
• cardiff_ex3101.htm (EX-31.1) — 11KB
• cardiff_ex3102.htm (EX-31.2) — 11KB
• cardiff_ex3201.htm (EX-32.1) — 4KB
• cardiff_ex3202.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 132KB
• 0001683168-25-008221.txt ( ) — 7814KB
• cdif-20250930.xsd (EX-101.SCH) — 60KB
• cdif-20250930_cal.xml (EX-101.CAL) — 67KB
• cdif-20250930_def.xml (EX-101.DEF) — 227KB
• cdif-20250930_lab.xml (EX-101.LAB) — 420KB
• cdif-20250930_pre.xml (EX-101.PRE) — 369KB
• cardiff_i10q-093025_htm.xml (XML) — 1209KB

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 45 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 54 Item 4.

Controls and Procedures

Controls and Procedures 54 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 56 Item 1A.

Risk Factors

Risk Factors 56 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 56 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 57 2 PART I FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS. CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 (Unaudited) and 2024 (Unaudited) 5 Condensed Consolidated Statements of Stockholders' (Deficit)/Equity for the Three and Nine Months Ended September 30, 2025 (Unaudited) and 2024 (Unaudited and Restated) 6-7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 (Unaudited) and 2024 (Unaudited and Restated) 8 Notes to Condensed Consolidated Financial Statements (Unaudited and Restated) 9 3 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2025 (UNAUDITED) AND DECEMBER 31, 2024 September 30, 2025 December 31, 2024 ASSETS Current assets Cash $ 232,033 $ 1,188,185 Accounts receivable, net 20,699,999 15,934,490 Prepaid and other current assets 112,514 89,901 Total current assets 21,044,546 17,212,576 Property and equipment, net 3,715 21,198 Land 540,000 540,000 Goodwill 5,666,608 5,666,608 Right of use – assets, net 281,514 406,950 Due from related party 4,979 4,979 Other assets 68,154 73,368 Total assets $ 27,609,516 $ 23,925,679 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (DEFICIT)/EQUITY Current liabilities Accounts payable and accrued expense $ 1,659,791 $ 1,379,760 Accrued expenses – related parties 4,722,691 4,553,057 Accrued interest 567,986 429,200 Right of use – lease liabilities 214,002 223,330 Notes payable – current portion 200,803 312,180 Line of credit 14,727,190 8,645,991 Convertible notes payable 50,000 105,000 Net liabilities of discontinued operations 238,285 238,285 Total current liabilities 22,380,748 15,886,

View Full Filing

View this 10-Q filing on SEC EDGAR